MaltSci 麦伴科研

Appearance

文献精选 > 近年高分"CAR-T疗法"研究（IF≥30，近5年）

Advances in CAR-T-cell therapy in T-cell malignancies. ​

文献信息 ​

DOI10.1186/s13045-024-01568-z
PMID38915099
期刊Journal of hematology & oncology
影响因子40.4
JCR 分区Q1
发表年份2024
被引次数8
关键词CAR-T细胞疗法, 挑战, 研究进展, T细胞恶性肿瘤, 靶抗原
文献类型Journal Article, Review, Research Support, Non-U.S. Gov't
ISSN1756-8722
页码49
期号17(1)
作者Rubing Zheng, Xiaojian Zhu, Yi Xiao

一句话小结 ​

本文回顾了嵌合抗原受体T细胞（CAR-T细胞）在治疗T细胞恶性肿瘤中的挑战与进展，指出了靶抗原共享导致的非特异性杀伤和细胞产品污染等问题，并探讨了相应的解决策略。研究为提高CAR-T细胞治疗在T细胞恶性肿瘤中的疗效和应用提供了重要的理论依据和创新思路。

在麦伴科研 (maltsci.com) 搜索更多文献 ​

CAR-T细胞疗法 · 挑战 · 研究进展 · T细胞恶性肿瘤 · 靶抗原

摘要 ​

近年来，嵌合抗原受体T细胞（CAR-T细胞）治疗在复发性或难治性B细胞血液恶性肿瘤的治疗中取得了显著进展。然而，CAR-T细胞治疗在治疗侵袭性T细胞恶性肿瘤方面尚未取得同样的成功。本文回顾了CAR-T细胞治疗在T细胞恶性肿瘤治疗中的挑战，并总结了该领域的前临床和临床研究进展。我们分析了针对T细胞恶性肿瘤的CAR-T细胞治疗临床试验，并根据靶抗原分类进行了分组。此外，本综述重点讨论了CAR-T细胞治疗所面临的主要挑战，包括由于T细胞靶抗原共享导致的非特异性杀伤，以及在制备过程中细胞产品的污染。本文还讨论了解决这些挑战的策略，提出了可能增强CAR-T细胞治疗在T细胞恶性肿瘤治疗中疗效和适用性的创新治疗方法。这些理念和策略为未来的研究提供了重要信息，以促进CAR-T细胞治疗在该领域的进一步发展和应用。

英文摘要 ​

Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of aggressive T-cell malignancies. This article reviews the challenges of CAR-T-cell therapy in treating T-cell malignancies and summarizes the progress of preclinical and clinical studies in this area. We present an analysis of clinical trials of CAR-T-cell therapies for the treatment of T-cell malignancies grouped by target antigen classification. Moreover, this review focuses on the major challenges encountered by CAR-T-cell therapies, including the nonspecific killing due to T-cell target antigen sharing and contamination with cell products during preparation. This review discusses strategies to overcome these challenges, presenting novel therapeutic approaches that could enhance the efficacy and applicability of CAR-T-cell therapy in the treatment of T-cell malignancies. These ideas and strategies provide important information for future studies to promote the further development and application of CAR-T-cell therapy in this field.

麦伴智能科研服务 ​

智能阅读回答你对文献的任何问题，帮助理解文献中的复杂图表和公式
定位观点定位某个观点在文献中的蛛丝马迹
加入知识库完成数据提取，报告撰写等更多高级知识挖掘功能

主要研究问题 ​

  1. CAR-T细胞疗法在T细胞恶性肿瘤中的具体挑战有哪些，如何影响治疗效果？
  2. 目前有哪些新兴的靶抗原分类正在被研究，以改善CAR-T细胞疗法对T细胞恶性肿瘤的疗效？
  3. 除了CAR-T细胞疗法，还有哪些新兴的免疫治疗方法在T细胞恶性肿瘤中显示出潜力？
  4. 针对T细胞恶性肿瘤，当前临床试验中使用的CAR-T细胞疗法的成功率和失败率分别是多少？
  5. 在CAR-T细胞疗法的制备过程中，如何有效减少细胞产品污染对治疗结果的影响？

核心洞察 ​

研究背景和目的 ​

近年来，嵌合抗原受体T细胞（CAR-T细胞）疗法在治疗复发/难治性B细胞血液恶性肿瘤方面取得了显著进展。然而，该疗法在治疗侵袭性T细胞恶性肿瘤方面尚未取得同样的成功。本研究旨在探讨CAR-T细胞疗法在T细胞恶性肿瘤中的应用挑战，并总结相关的前临床和临床研究进展，以期为未来研究提供指导。

主要方法/材料/实验设计 ​

本综述采用文献回顾的方式，分析了针对T细胞恶性肿瘤的CAR-T细胞疗法的临床试验，按靶抗原分类进行总结。同时，讨论了在CAR-T细胞制备和应用过程中遇到的主要挑战，如靶抗原共享导致的非特异性杀伤和产品污染等。研究中还提出了一些克服这些挑战的策略和新型治疗方法。

Mermaid diagram

关键结果和发现 ​

  1. 靶抗原的多样性：研究指出，针对T细胞恶性肿瘤的潜在靶抗原包括CD5、CD7、CD30等，这些靶点在不同的T细胞亚型中具有不同的表达模式。
  2. 主要挑战：
    • 靶抗原共享：许多靶抗原在正常T细胞和CAR-T细胞中也有表达，导致自我攻击（fratricide）和自杀（suicide）现象，严重影响CAR-T细胞的疗效。
    • 产品污染：在CAR-T细胞制备过程中，可能会出现正常和恶性T细胞的混合，影响治疗效果。
  3. 克服策略：研究者们通过基因编辑技术下调或敲除CAR-T细胞上的靶抗原，采用双靶点或多靶点CAR设计，增强靶向特异性和安全性。

主要结论/意义/创新性 ​

CAR-T细胞疗法在T细胞恶性肿瘤治疗中显示出良好的潜力，尽管面临诸多挑战。靶抗原的选择、基因编辑技术的应用以及新型细胞载体的探索，均为提高治疗效果提供了新的方向。这些研究为未来T细胞恶性肿瘤的治疗提供了重要的理论基础和实践指导。

研究局限性和未来方向 ​

  1. 局限性：目前的研究主要集中在特定靶抗原的临床试验上，缺乏大规模的临床数据支持。同时，基因编辑技术的长期安全性和有效性仍需进一步验证。
  2. 未来方向：建议未来的研究应集中于探索新的靶抗原、优化CAR-T细胞的设计，并开展更大规模的临床试验，以验证不同治疗策略的有效性和安全性。
部分内容
研究背景和目的探讨CAR-T细胞疗法在T细胞恶性肿瘤中的应用挑战
主要方法/材料/实验设计文献回顾与靶抗原分类分析
关键结果和发现多样性靶抗原、靶抗原共享、产品污染问题
主要结论/意义/创新性CAR-T细胞疗法潜力大，需优化靶抗原选择和设计
研究局限性和未来方向需更多临床数据与新靶点探索

参考文献 ​

  1. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. - Robert Zeiser;Bruce R Blazar - The New England journal of medicine (2017)
  2. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. - Robbie G Majzner;Johanna L Theruvath;Anandani Nellan;Sabine Heitzeneder;Yongzhi Cui;Christopher W Mount;Skyler P Rietberg;Miles H Linde;Peng Xu;Christopher Rota;Elena Sotillo;Louai Labanieh;Daniel W Lee;Rimas J Orentas;Dimiter S Dimitrov;Zhongyu Zhu;Brad St Croix;Alberto Delaidelli;Alla Sekunova;Ezio Bonvini;Siddhartha S Mitra;Martha M Quezado;Ravindra Majeti;Michelle Monje;Poul H B Sorensen;John M Maris;Crystal L Mackall - Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
  3. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. - Youn H Kim;Madeleine Duvic;Erik Obitz;Robert Gniadecki;Lars Iversen;Anders Osterborg;Sean Whittaker;Timothy M Illidge;Thomas Schwarz;Roland Kaufmann;Kevin Cooper;Kim M Knudsen;Steen Lisby;Ole Baadsgaard;Susan J Knox - Blood (2007)
  4. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. - Céline Bossard;Maria Pamela Dobay;Marie Parrens;Laurence Lamant;Edoardo Missiaglia;Corinne Haioun;Antoine Martin;Bettina Fabiani;Richard Delarue;Olivier Tournilhac;Mauro Delorenzi;Philippe Gaulard;Laurence de Leval - Blood (2014)
  5. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. - Fengtao You;Yinyan Wang;Licui Jiang;Xuejun Zhu;Dan Chen;Lei Yuan;Gangli An;Huimin Meng;Lin Yang - American journal of cancer research (2019)
  6. Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. - Khaled Sanber;Bipin Savani;Tania Jain - British journal of haematology (2021)
  7. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. - Takahiro Kamiya;Desmond Wong;Yi Tian Png;Dario Campana - Blood advances (2018)
  8. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. - Jing Pan;Yue Tan;Guoling Wang;Biping Deng;Zhuojun Ling;Weiliang Song;Samuel Seery;Yanlei Zhang;Shuixiu Peng;Jinlong Xu;Jiajia Duan;Zelin Wang;Xinjian Yu;Qinlong Zheng;Xiuwen Xu;Ying Yuan;Fangrong Yan;Zhenglong Tian;Kaiting Tang;Jiecheng Zhang;Alex H Chang;Xiaoming Feng - Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
  9. CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy. - Miriam Y Kim;Matthew L Cooper;Miriam T Jacobs;Julie K Ritchey;Julia Hollaway;Todd A Fehniger;John F DiPersio - JCI insight (2021)
  10. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. - Paul M Maciocia;Patrycja A Wawrzyniecka;Brian Philip;Ida Ricciardelli;Ayse U Akarca;Shimobi C Onuoha;Mateusz Legut;David K Cole;Andrew K Sewell;Giuseppe Gritti;Joan Somja;Miguel A Piris;Karl S Peggs;David C Linch;Teresa Marafioti;Martin A Pule - Nature medicine (2017)

引用本文的文献 ​

  1. Nanomaterial-based cancer immunotherapy: enhancing treatment strategies. - Mengxiang Tian;Xionglin Liu;Haiping Pei - Frontiers in chemistry (2024)
  2. Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress. - Huageng Huang;Le Yu;Huawei Weng;Wei Zhang;Zhao Wang;Lin Wang;He Huang - Journal of hematology & oncology (2024)
  3. Emerging Multifunctional Biomaterials for Addressing Drug Resistance in Cancer. - Mohamed El-Tanani;Syed Arman Rabbani;Rasha Babiker;Yahia El-Tanani;Shakta Mani Satyam;Thantrira Porntaveetus - Biology (2025)
  4. Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges. - Francesco Branda;Chiara Romano;Grazia Pavia;Viola Bilotta;Chiara Locci;Ilenia Azzena;Ilaria Deplano;Noemi Pascale;Maria Perra;Marta Giovanetti;Alessandra Ciccozzi;Andrea De Vito;Angela Quirino;Nadia Marascio;Giovanni Matera;Giordano Madeddu;Marco Casu;Daria Sanna;Giancarlo Ceccarelli;Massimo Ciccozzi;Fabio Scarpa - Viruses (2025)
  5. CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights. - Li-Ya Cao;Yue Zhao;Yang Chen;Pan Ma;Jiang-Chuan Xie;Xin-Mei Pan;Xin Zhang;Yong-Chuan Chen;Qian Wang;Lin-Li Xie - Frontiers in immunology (2025)
  6. Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer. - Kangkang Ji;Lin Guo;Dianbao Zuo;Mingqian Feng;Xin Chen;Zhenggang Zhao;Jing Tang;Guoping Chen - Frontiers in immunology (2025)
  7. T cells in cancer: mechanistic insights and therapeutic advances. - Jingjing Pu;Ting Liu;Yi Zhou;Mengping Chen;Xuehang Fu;Yike Wan;Junying Wang;Binzhen Chen;Amit Sharma;Veronika Lukacs-Kornek;Ingo G H Schmidt-Wolf;Jian Hou - Biomarker research (2025)
  8. CD7 CAR-T therapy: current developments, improvements, and dilemmas. - Linjuan Wang;Shaowei Qiu - Blood science (Baltimore, Md.) (2025)

© 2025 MaltSci 麦伴科研 - 我们用人工智能技术重塑科研